Background: This research evaluates the treatment benefits of platelet-rich plasma (PRP) and erythropoietin (EPO) on diabetic nephropathy and hepatopathy in rats.
Methods: Thirty male rats were separated into five groups: control, diabetic control, PRP-treated diabetic (1 mL PRP subcutaneously twice weekly), EPO-treated diabetic (300 units/kg EPO subcutaneously three times weekly), and a combination of PRP and EPO treatment (1 mL PRP twice weekly and 300 units/kg EPO three times weekly). Diabetes was induced using streptozotocin (65 mg/kg), and treatments were administered over four weeks. Serum markers for renal and hepatic function, oxidative stress indices, and histopathological changes in liver and kidney tissues were assessed.
Results: In diabetic rats, serum urea, creatinine, and liver enzymes (ALT, AST, ALP, LDH, GGT) increased significantly (p<0.05), while treatment with PRP, EPO, or both significantly reduced ALT, AST, ALP, LDH, and GGT (except in the combined group for GGT; p>0.05). Renal and hepatic SOD decreased significantly in diabetes (p<0.05) but improved with treatment, especially in the combined group (p<0.05). Renal TAC increased in diabetes and decreased significantly after treatment (p<0.05). No significant changes were observed in GPX or MDA levels (p>0.05). Damage in kidney and liver tissues were obtained in diabetic group. Histopathological improvements were evident, in hepatocyte integrity and glomerular structure, with EPO and PRP treatments.
Conclusion: The results emphasize the potential of EPO and PRP as complementary therapeutic strategies to reduce diabetes-induced oxidative damage and structural deterioration in liver and kidney tissues. However, further adjunctive approaches are required to achieve comprehensive organ protection.